Overcoming resistance to radiation is a great challenge in cancer therapy. Here, we highlight that targeting valosin-containing protein (VCP) improves radiation sensitivity in esophageal squamous cell carcinoma (ESCC) cell lines and show the potential of using VCP as a prognosis marker in locally advanced ESCC treated with radiation therapy. Esophageal squamous cell carcinoma cell lines with high VCP expression were treated with VCP inhibitor combined with radiotherapy. Cell proliferation, colony formation, cell death, and endoplasmic reticulum (ER) stress signaling were evaluated. Moreover, patients with newly diagnosed locally advanced ESCC who were treated with radiotherapy were analyzed. Immunohistochemistry was used to detect the expression of VCP. The correlation between overall survival and VCP was investigated. Esophageal squamous cell carcinoma cells treated with VCP inhibitor and radiotherapy showed attenuated cell proliferation and colony formation and enhanced apoptosis. Further investigation showed this combined strategy activated the ER stress signaling involved in unfolded protein response, and inhibited the ER-associated degradation (ERAD) pathway. Clinical analysis revealed a significant survival benefit in the low VCP expression group. Targeting VCP resulted in antitumor activity and enhanced the efficacy of radiation therapy in ESCC cells in vitro. Valosin-containing protein is a promising and novel target. In patients with locally advanced ESCC who received radiotherapy, VCP can be considered as a useful prognostic indicator of overall survival. Valosin-containing protein inhibitors could be developed for use as effective cancer therapies, in combination with radiation therapy. K E Y W O R D S endoplasmic reticulum stress, esophageal squamous cell carcinoma, prognosis, radiation resistance, valosin-containing protein | 3465 LUO et aL.
| INTRODUC TI ON
Esophageal cancer is a major global health concern. 1 According to histological classification, squamous cell carcinoma and adenocarcinoma are the 2 main types of esophageal cancer. 2 In the past few decades, adenocarcinoma has been the most common type of esophageal cancer in developed countries; however, esophageal squamous cell carcinoma (ESCC) still accounts for nearly 70% of cases of esophageal cancer around the world, especially in Asia. 3, 4 Radiotherapy, in combination with chemotherapy, is widely used in the management of locally advanced ESCC. 5 Despite incredible improvements in cancer treatment, radiation resistance leads to treatment failure and results in poor outcomes. 6, 7 Therefore, it is crucial to select biomarkers indicative of eligible patients who could benefit from this treatment protocol.
Valosin-containing protein (VCP), also known as p97 in mammals or cdc48 in yeast, is a hexameric ATPase of the AAA family. 8 Valosincontaining protein is described as a crucial chaperone for regulating folding or unfolding substrate proteins in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway. 9, 10 With respect to the high protein synthesis burden and possible aneuploidy in many kinds of tumor cells, the ERAD pathway has a central role in regulating cancer cell proliferation. 11 Over the past few years, high expression of VCP has been described and found to correlate with disease outcomes in various cancer patients who received surgical resection. [12] [13] [14] [15] [16] [17] Recently, several VCP inhibitors have been developed. [18] [19] [20] Among these specific inhibitors, NMS-873 was initially developed as an allosteric, non-ATP-competitive, and potent noncovalent VCP inhibitor that impairs the ERAD pathway, activates the unfolded protein response (UPR), and induces apoptosis. 20 In addition, other findings have revealed VCP as a potential target and inhibiting VCP has been associated with improved antitumor activity in vitro and in vivo. 21, 22 To date, the role of VCP in enhancing tumor radiation sensitivity has not been characterized in ESCC cell lines. Moreover, the significance of VCP expression in locally advanced ESCC patients who had undergone radiotherapy was of little concern.
Finding a valuable biomarker for treatment stratification and prognostic prediction is a challenge in cancer therapy. The objectives of this study were to investigate the value of VCP inhibitor in improving radiation resistance. We went further, by attempting to identify the feasibility of using VCP as a prognostic marker for patients with locally advanced ESCC who have received radiotherapy.
| MATERIAL S AND ME THODS

| Reagents
NMS-873 (purity >98%) was purchased from Dalian Meilun Biotechnology (CAS: 1418013-75-8), the compound was dissolved in DMSO and stored at 4°C. Primary Abs used for the western blot analysis included inositol-requiring enzyme 1α (IRE1α) (14C10; Cell Signaling Technology), X-box binding protein 1 (XBP-1(s)) (D2C1F; Cell Signaling Technology), phospho-protein kinase RNA-like ER kinase (p-PERK) (DF7576; Affinity Biotechnology), phospho-eukaryotic initiation factor 2α (p-eIF2α) (119A11, Cell Signaling Technology), activating transcription factor 6 (ATF6) (D4Z8V; Santa Cruz Biotechnology), binding immunoglobulin protein (BiP) (C50B12; Cell Signaling Technology), and C/EBP homologous protein (CHOP) (D46F1; Cell Signaling Technology). Antibody to detect VCP was purchased from Abcam (ab11433), the GAPDH (KM9002T) and βactin (KM9001T) were obtained from Sungene Biotech. Secondary Ab included goat anti-mouse IgG-HRP (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004) were from Santa Cruz Biotechnology. All cells were cultured in a humidified atmosphere at 37°C with 5% CO 2 . All cells were subjected to cytogenetic testing and confirmed.
| Cell lines and cell culture
| Cell viability assay
In general, cancer cells were plated in a 96-well plate format at 3000 cells per well in 0.2 mL medium and incubated overnight. Next day, the cells were treated with different amounts of NMS-873. After incubation for 24, 48, or 72 hours, cancer cell viability was measured by the MTT assay. The optical absorbance was determined at 490 nm using a microplate reader (Thermo Fisher Scientific). Dose response curves were fitted and inhibitory concentration values were calculated for each cell line.
| RNA interference experiments
Specific and nontargeting siRNA were purchased from SunYa Biotechnology. KYSE70 and KYSE140 cells were seeded in 6-well plates and grown to 40%-50% confluency in serum-containing medium (without penicillin/streptomycin). Tumor cells were transfected with the VCP targeting siRNAs using Lipofectamine RNAiMAX (13778150; Thermo Fisher Scientific) following the manufacturer's instructions.
The knockdown efficiency was analyzed by western blot experiments.
| Colony formation assays
Cells were seeded (400 cells/well for KYSE140; 200 cells/well for KYSE70) in 6-well plates in 2 mL medium and incubated for 24 hours at 37°C in a 5% CO 2 incubator. Then the culture media were replaced with media containing appropriate amounts of NMS-873. Next day, the cells were irradiated with a TrueBeam SN1403 accelerator (Varian Medical Systems). Doses included 0, 2, 4, 6, 8, 10, and/or 12 Gy. These cells were further incubated for 7-14 additional days until the colonies were optimal. After aspirating the media and being fixed with methanol, 0.5% crystal violet was used to stain the colonies for 10 minutes, then they were washed with water. Each well was air-dried and colonies were visualized under a microscope; colonies containing 50 cells or more were counted using the Image-Pro Plus software (version 6.0) program (Media Cybernetics). The classic multitarget single hit model was applied to plot the dose survival curves. Survival fraction (SF) = 1 − (1 − e −D/D0 )N, where the mean lethal dose (D0) represents the dose needed to decrease the fraction of surviving cells to 37% of its previous value, N is the extrapolation number, and the quasithreshold dose (Dq) indicates repair capacity of tumor cells after radiation therapy. Radiation sensitivity parameters included survival fraction at 2 Gy (SF2), D0, Dq, and the sensitivity enhancement ratio was calculated. The sensitivity enhancement ratio was calculated by dividing D0 in the control group by D0 in the treatment group. 23, 24 Three independent experiments were carried out for each cell line, with each treatment undertaken in triplicate.
| Annexin V apoptosis assay
Cancer cells (8 × 10 5 cells for KYSE140; 4 × 10 5 cells for KYSE70) were seeded in 6-well plates using appropriate culture media and incubated overnight. Cells were treated with NMS-873 and/or irradiated with 6 Gy and allowed to incubate for 48 hours. After cells were collected and stained with annexin V-FITC and propidium iodide (PI), apoptosis assay was carried out by flow cytometry using a BD FACSCalibur Flow Cytometer (BD Biosciences). 
| Western immunoblot analysis
| Immunohistochemical staining
| Statistical analysis
Statistical analyses were carried out using SPSS version 20.0 (IBM Software Group) and Prism 7 (GraphPad Software). Student's t test and/or one-way or two-way ANOVA was used for statistical analyses. The Bonferroni multiple comparisons test was applied where necessary. Overall survival (OS) was estimated using the Kaplan-Meier methodology; the log-rank test was used to detect potential differences amongst the various variables. Univariate and multivariate Cox proportional hazard regression models were analyzed to identify potential prognostic factors of OS. A 2-tailed P < .05 was considered to be significant for all of the statistical analyses.
| RE SULTS
| Treatment with VCP inhibitor attenuates tumor cell proliferation
To measure intracellular protein expression, whole cell lysates were generated from 7 different ESCC cells and 1 normal esophageal epithelial cell. Expression of VCP was significantly lower in normal cells compared with tumor cells. Among the 7 different ESCC cells, KYSE140 is associated with the highest expression of VCP ( Figure 1A,B ). Therefore, proliferation assay was carried out to determine the effect of VCP inhibitor on cancer cells (KYSE70 and KYSE140). Our results showed that NMS-873 reduced cell proliferation in a dose-dependent manner ( Figure 1C ,D). We also observed that the IC 10 values are different for KYSE70 and KYSE140 (120 nmol/L and 90 nmol/L, respectively). These findings suggest that VCP inhibitor is cytotoxic to tumor cells. In addition, we tested the effect of VCP inhibitor in the remaining tumor cell lines and 1 normal esophageal epithelial cell line. The final analysis revealed that the sensitivity of VCP inhibitor was correlated with relative VCP expression ( Figure 1E ).
| Inhibition of VCP enhances the efficacy of radiation
Drugs that can enhance radiation sensitivity are essential in cancer treatment. To evaluate the efficacy of VCP inhibitor in combination with radiation therapy, colony formation assays were undertaken in ESCC cells (KYSE70 and KYSE140). For subsequent investigations, both KYSE70 cells and KYSE140 cells were treated with NMS-873 at the concentrations listed above. The results indicated that there were no visible signs of toxicity for tumor cells.
Radiation therapy combined with NMS-873 showed a significant decrease in the surviving fraction in both KYSE70 and KYSE140 cells when compared with radiation therapy alone (Figure 2A,B) .
These outcomes showed an increased sensitivity to radiation therapy when combined with VCP inhibitor.
Additionally, to confirm the radiation sensitization effect of VCP inhibition, we undertook siRNA inference experiments. Knockdown of VCP resulted in increased sensitivity to radiation therapy ( Figure 2C -F). Together, these data suggested that inhibition of VCP sensitizes ESCC cells to radiation therapy.
| Treatment with VCP inhibitor induces cell death through the apoptotic pathway
On the basis of the above data, radiation therapy combined with VCP inhibitor was effective in ESCC cells. To determine whether this combined strategy induces cell death by apoptosis, we undertook annexin V/PI staining assays. As shown in Figure 3A -C, a significant increase in the percentages of cancer cells undergoing early apoptosis (annexin V + /PI − ) and late apoptosis (annexin V − /PI + ) was observed in both the radiation therapy group and the combined group. In addition, the combined strategy resulted in a higher apoptosis rate than radiation therapy alone. We also found that VCP inhibitor alone had limited effects on apoptosis in cancer cells.
Furthermore, we evaluated the toxicity of VCP inhibitor in normal esophageal epithelial cells. The results indicated that VCP inhibitor is slightly toxic in normal cells, and VCP inhibitor combined with radiation therapy is insignificant in inducing apoptosis ( Figure 3D ). Collectively, these data suggested that VCP inhibition enhanced radiation-mediated apoptosis and this enhancement was tumor cell-specific.
| Valosin-containing protein inhibitor and radiation therapy combined result in enhanced UPR
An accumulation of unfolded proteins and misfolded proteins resulted in ER stress response in tumor cells. 25 The ER stress response is an adaptive mechanism that contributes to cell survival; however, increased ER stress is associated with CHOP overexpression, and would predispose the cells to ER stress-mediated apoptosis. 26, 27 Previous studies described radiation-induced ER stress in cancer cells. [27] [28] [29] Valosin-containing protein inhibitors have been reported to trigger the misfolded protein accumulation and activate the UPR in various cancer cell lines. 30 Therefore, we pre- 
| High VCP expression in ESCC is associated with poor survival
Next, we analyzed the association between VCP expression and survival in patients of locally advanced ESCC treated with radiotherapy. In general, VCP expression was significantly increased in the cytoplasm of tumor cells by immunohistochemistry ( Figure 5A-E) . All the samples were evaluated carefully. High expression of VCP was detected in 46 patients, whereas low VCP expression was found in 39 patients (Table 1) 
| D ISCUSS I ON
The current study shows that ESCC cell lines are associated with varying levels of VCP. In line with previous reports, our analysis also showed cancer cells with high VCP expression are sensitive to VCP inhibitor. We also observed that VCP inhibitor acts as a sensitizer when combined with radiation therapy; the potential molecular mechanisms are combined strategies that result in enhanced and prolonged ER stress, which can trigger UPR, especially the PERK-eIF2α-CHOP pathway, thereby inducing cell death. In addition, compared with the high VCP expression group, ESCC patients with low expression of VCP treated by radiotherapy were associated with favorable survival. Further analysis suggested that VCP is an independent prognostic factor. Consequently, our results indicated that VCP is a biomarker for predicting radiation resistance and targeting VCP enhances the efficacy of radiation therapy.
Valosin-containing protein is essential for misfolded protein disaggregation and degradation and it is also involved in genome integrity. 25 It is well known that cancer cells are always exposed to various factors that alter protein homeostasis, and misfolded proteins accumulate inside the ER; therefore, invoking ER stress. 31 In order to restore ER proteostasis, tumor cells evoke various kinds of adaptive mechanisms including the UPR and ERAD. With the help of VCP, one key component of the proteasome, misfolded proteins were transported from the ER to the cytosol for further degradation. 25 Elevated levels of VCP appear to be cytoprotective for tumor cells, cells. 33 In the current study, our findings suggest that VCP expression is varied in ESCC cell lines. Treatment with VCP inhibitor led to decreased cell proliferation; in particular, there is a strong correlation between VCP expression and treatment response to VCP inhibitor.
Targeting VCP is a promising strategy for antitumor therapy.
NMS-873, one of the VCP inhibitors, has been shown to cause cancer cell death by inducing ER stress. 20 Our analysis also suggests a relatively mild ER stress triggered by this compound. Molecular mechanisms involved in cytotoxicity induced by NMS-873 might both inhibit the ERAD pathway and induce the UPR pathway.
Sorafenib, a multikinase inhibitor, has been proved to target VCP, thereby inducing hepatocellular cancer cell death. 34 Recently, the combinatorial therapeutic strategy of targeting VCP has been explored. Valosin-containing protein inhibitors in combination with oncolytic virus M1 was a promising treatment for hepatocellular carcinoma. 35 Bastola et al described the preclinical activity of VCP inhibitors in ovarian cancer cells, and final outcomes showed that VCP inhibitors were able to induce ER stress, cause cell cycle arrest, and trigger caspase-mediated cell death. Thus, VCP inhibitor can be used as a single agent or combined with other antitumor compounds. 22 The existence of radiation resistance in cells remains one of the most critical obstacles in anticancer therapy. 36 Mice xenografted glioma models treated with hypofractionated radiotherapy were analyzed using reverse-phase protein array; the results revealed VCP levels were correlated with radiation resistance. 37 Our analysis also gives evidence that VCP could act as a potential radiation resistance biomarker. In addition, we observed that radiation therapy activated the UPR signaling pathway and induced ER stress. Similar results were also reported in normal cells and tumor cells. 28, 38 This is mainly because radiation therapy causes misfolded protein accumulation and activates the UPR pathway. 39 Nevertheless, the role of VCP in radiation resistance was not well investigated. Detailed analyses are needed to fully understand the potential mechanisms.
The UPR consists of the IRE1-XBP-1(s) signaling pathway, the PERK-eIF2α pathway, and the ATF6 pathway. 29 Previous analyses described that both radiation therapy and VCP inhibitors were able to induce the UPR through activating the IRE1-XBP-1(s) signaling pathway and the PERK-eIF2α pathway, without triggering the F I G U R E 4 Valosin-containing protein inhibitor combined with radiation therapy (RT) enhanced and prolonged the activation of unfolded protein response (UPR) in esophageal squamous cell carcinoma cells. A, KYSE70 cells were treated with vehicle, NMS-873 (120 nmol/L), RT (6 Gy), or RT/NMS-873, and the proteins in UPR pathways were analyzed by western blot. B, Quantification of inositol-requiring enzyme 1α (IRE1α), X-box binding protein 1 (XBP-1(s)), and binding immunoglobulin protein (BiP) from (A). C, Quantification of phospho-protein kinase RNA-like endoplasmic reticulum kinase (p-PERK), phospho-eukaryotic initiation factor 2α (p-eIF2α), and activating transcription factor 6 (ATF6) from (A). D, KYSE70 cells were treated with vehicle, NMS-873 (120 nmol/L), RT (6 Gy), or RT/NMS-873, and C/EBP homologous protein (CHOP) was detected by western blot analysis. E, Quantification of CHOP from (D). Data are mean ± SD (n = 3). *P ˂ .05; **P ˂ .001. n.s., not significant, P > .05 ATF6 pathway. 35, 39 Similarly, our results also showed the expression of ATF6 showed no difference when treated with radiation therapy and/or NMS-873. Furthermore, our analysis indicated VCP inhibitor has a synergistic effect with radiation therapy. Misfolded proteins induced by radiation therapy accumulate in cancer cells, and can be transported out of the ER through the ERAD pathway.
NMS-873 was effective in inhibiting the ERAD pathway and resulted in a large quantity of misfolded proteins accumulated in the ER. Immediately, both the activated UPR pathway and the accumulated misfolded protein caused enhanced and prolonged ER stress in tumor cells. When ER stress becomes insurmountable, cell apoptosis ensues ( Figure 6 ).
Valosin-containing protein has been investigated for a long time.
In previous studies, the prognostic potential of VCP expression was evaluated in different types of solid cancers and hematological tumors. Yamamoto et al 15, 16 reported that high expression of VCP was associated with increased incidence of cancer progression in gastric carcinoma and esophageal cancer patients who received surgical resection. In human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma patients treated with surgery, VCP expression evaluated by immunohistochemistry indicated that this protein could be used as a prognostic marker, and VCP intensity was apparently uncorrelated with HPV status. 12 Zhu et al recently investigated the correlation between VCP expression and primary orbital mucosa-associated lymphoid tissue in lymphoma patients treated by curative resection; the results showed that high expression of VCP was significantly correlated with recurrence, enlarged tumor size, and reduced survival. 17 The novelty of our analysis is that elevated expression of VCP was indicative of unfavorable survival in ESCC patients who received radiotherapy. We also showed that VCP can serve as an independent prognostic factor for this patient cohort. Additionally, positive lymph node was associated with tumor invasion and poor survival in esophageal cancer. 40, 41 The present study also found negative lymph node was an independent favorable prognostic marker in locally advanced ESCC patients treated with radiotherapy. TA B L E 2 Cox proportional hazards regression for overall survival in patients with esophageal squamous cell carcinoma F I G U R E 6 Mechanisms of targeting valosin-containing protein (VCP) enhance the efficacy of radiation therapy (RT) in human esophageal squamous cell carcinoma cell lines. ATF, activating transcription factor; CHOP, C/EBP homologous protein; eIF2α, eukaryotic initiation factor 2α; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated degradation IRE1, inositol-requiring enzyme 1; PERK, protein kinase RNA-like endoplasmic reticulum kinase; UPR, unfolded protein response; XBP-1s, X-box binding protein 1 bias could exist. Valosin-containing protein as a radiation resistance biomarker was not well characterized from a clinical perspective.
Therefore, our analysis should be interpreted with caution and additional studies are needed to support the results.
In conclusion, the findings of this study suggest that VCP plays a vital role in regulating the cell viability of ESCC cells. Targeting VCP offers a new strategy in enhancing radiation sensitivity. In addition, an elevated expression of VCP is associated with unfavorable survival in locally advanced ESCC patients treated with radiotherapy.
Valosin-containing protein expression has the potential to be used as an independent prognostic factor. 
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